This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Fasting blood glucose ( sugar / BM ) in management of diabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the categories of fasting blood glucose identified by American Diabetes Association (ADA) Clinical Practice Recommendations:
    • 4·4-6·7 mmol L , 'good';
    • > 6·7-7·8 mmol L , 'acceptable';
    • > 7·8 mmol L , 'bad'
  • the British Diabetes Association has defined target values for fasting blood glucose levels as:
    • fasting blood glucose levels of 4-7 mmol/litre
    • self monitored blood glucose levels before meals of between 4 and 7 mmol/l
  • JBS 2 suggests optimal target for glycaemic control in diabetes is a fasting or pre-prandial glucose value of 4.0–6.0 mmol/ l (1)

Reference:

  1. American Diabetes Association. Position Statement: Standards of Medical Care for Patients with Diabetes Mellitus. Diabetes Care 1998;21 (Suppl. 1):S23-S31.
  2. British Diabetic Association (December 1998). United Kingdom Prospective Diabetes Study (UKPDS) - Implications for the care of people with type 2 diabetes.
  3. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Supp 5).

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.